CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas

Author: Benzinga Newsdesk | April 08, 2024 05:03pm

On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company’s previously announced dispute with Juventas Cell Therapy Ltd., an emergency arbitrator appointed by the Hong Kong International Arbitration Centre (the “HKIAC”) issued an Order on April 5, 2024, granting the emergency injunctive relief CASI sought pending the determination of the arbitration proceeding initiated with the HKIAC in connection with the dispute (the “Arbitration Proceeding”). The emergency arbitrator’s Order, among other things, prohibits Juventas from commercializing CNCT19 by itself or through another third party.  The emergency arbitrator also noted in the Order that the parties shall cooperate to reach a temporary arrangement that allows them to provide CNCT19 to new patients.

Posted In: CASI